BioStock: Coegin Pharma seeks new opportunities through merger

Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum. The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia and chronic kidney diseae, is grabbing the opportunity to strengthen its drug development portfolio by putting strong focus on diabetes complications. BioStock was able to get in touch with Professors Anna Hultgårdh and Jan Nilsson, two internationally-recognised experts in diabetes complications to learn more about what the acquisition will mean for Coegin going forward.

Read the interview with Professors Anna Hultgårdh and Jan Nilsson at biostock.se:

https://www.biostock.se/en/2022/03/coegin-pharma-seeks-new-opportunities-through-merger/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/